Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 34Urinary Bladder Neoplasms 29Neoplasm Metastasis 20Lung Neoplasms 19Ovarian Neoplasms 18Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Neoplasms 13Nasopharyngeal Carcinoma 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Recurrence 9Fallopian Tube Neoplasms 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 4Hodgkin Disease 4Colonic Neoplasms 4

Interventions

paricalcitol 1Taxes 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Pancreatic Cancer × Gemcitabine × 90 days × Clear all
NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡